Stockscreener 앱 받기
4.69
3.30%
-0.16
시장 영업 전:
4.62
-0.07
-1.49%
An 2 Therapeutics Inc 주식(ANTX)의 최신 뉴스
Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with - GlobeNewswire
Beam Therapeutics (BEAM) Reveals Encouraging Results From Risto-Cel Phase 1/2 BEACON Study - Yahoo Finance
Dianthus Therapeutics Inc (DNTH): FDA Makes Trials Easier - Yahoo Finance
Spotlighting Abeona Therapeutics And 2 More High Growth Stocks Insiders Favor - Yahoo Finance
Obsidian Therapeutics to Present OBX-115 Phase 2 Clinical Data in Advanced Melanoma in Oral Presentation at 2026 ASCO Annual Meeting - Business Wire
Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia - GlobeNewswire
Analysts Adjust Cadrenal Therapeutics, Inc. (CVKD) Valuation After Including CAD-1005 Program - Yahoo Finance
ZEVRA THERAPEUTICS, INC. ($ZVRA) CEO 2025 Pay Revealed - Quiver Quantitative
MapLight Therapeutics: Strong Balance Sheet Ahead of Crucial Phase 2 Readouts in Q3 2026 - AlphaStreet
Allogene Therapeutics, Inc. Files Form 8-K Current Report with SEC on April 13, 2026 2 - Minichart
Allogene Therapeutics, Inc. (ALLO) Discusses Interim Futility Analysis from Pivotal Phase II ALPHA 3 Trial in First-Line Consolidation Large B-Cell LymphomaSlideshow (NASDAQ:ALLO) 2026-04-14 - Seeking Alpha
ALLO Stock Jumps As Pivotal ALPHA3 CAR-T Data Loom - StocksToTrade
After layoffs, biotech exits 2 Boston-area leases - NBC Boston
AQUESTIVE THERAPEUTICS, INC. (AQST) DEADLINE ALERT - GlobeNewswire
INVESTOR ALERT: Soleno Therapeutics Inc. (SLNO) Investors - GlobeNewswire
Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14 - Yahoo Finance
Cognition Therapeutics, Inc. CEO Lisa Ricciardi to Present at 25th Annual Needham Virtual Healthcare Conference - Quiver Quantitative
OYE Therapeutics achieves first patient first dose in 505(b)(2) bridging study - Purdue Research Foundation
[SCHEDULE 13G/A] Indaptus Therapeutics, Inc. Amended Passive Investment Disclosure - Stock Titan
FDA grants Fast Track to Context Therapeutics (CNTX) CTIM-76 in platinum-resistant ovarian cancer - Stock Titan
Beam Therapeutics Announces Publication of BEACON Phase 1/2 Data for risto-cel in Patients with Sickle Cell Disease (SCD) in The New England Journal of Medicine - GlobeNewswire
Rapport Therapeutics to Present New Phase 2 Treatment - GlobeNewswire
United Therapeutics Soars as Clinical Trials Meet Key Endpoints - StocksToTrade
Plus Therapeutics, Inc. Announces 1-for-25 Reverse Stock Split Effective April 2, 2026 | PSTV Stock News - Quiver Quantitative
To keep its Nasdaq listing, Plus Therapeutics enacts 1-for-25 split - Stock Titan
AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease - Business Wire
Relmada Therapeutics: 2 New Assets, 2 New 'Blockbusters'? I'd Wait And See (NASDAQ:RLMD) - Seeking Alpha
Protara Therapeutics (TARA) sustains 68% CR in ADVANCED-2 and activates $5.25 warrants - Stock Titan
Beam Therapeutics Inc. (BEAM) Discusses Topline Phase I/II Data for BEAM-302 in Alpha-1 Antitrypsin DeficiencySlideshow (NASDAQ:BEAM) 2026-03-27 - Seeking Alpha
Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 - Finviz
Sarepta Therapeutics, Inc. (SRPT) Discusses Preliminary Phase I/II Data for SRP-1001 in FSHD1 and SRP-1003 in DM1Slideshow (NASDAQ:SRPT) 2026-03-25 - Seeking Alpha
Denali Therapeutics Inc.: Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II) - FinanzNachrichten.de
Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease - GlobeNewswire
Apogee Therapeutics Gains Momentum Amid Phase 2 Study Success - timothysykes.com
Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026 - GlobeNewswire
Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026 - GlobeNewswire
Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis - GlobeNewswire
Dementia trial drug slowed neuropsychiatric decline 86% vs placebo - Stock Titan
Structure Therapeutics Inc. (GPCR) Discusses Positive Topline Results from ACCESS II and Related Studies of Aleniglipron Oral GLP-1Slideshow (NASDAQ:GPCR) 2026-03-16 - Seeking Alpha
Relay Therapeutics (RLAY) shows 11.1-month PFS with zovegalisib combo in PI3Kα-mutated breast cancer - Stock Titan
Structure Therapeutics (NASDAQ: GPCR) shows 16% weight loss in Phase 2 oral GLP-1 trial - Stock Titan
Pill from Structure Therapeutics helped patients lose about 40 lbs - Stock Titan
Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study - PR Newswire
Inhaled IPF drug from United Therapeutics slows lung scarring in trial - Stock Titan
Tenax Therapeutics Inc (TENX) Reports Q4 Earnings - AlphaStreet
Cassava Sciences Announces Name Change to Filana Therapeutics, Inc. - Yahoo Finance
Trevi Therapeutics Announces Completion of End-of-Phase 2 - GlobeNewswire
Trevi Therapeutics Announces Completion of End-of-Phase 2 Meeting with the FDA, Gaining Alignment for Its Development Program for Idiopathic Pulmonary Fibrosis-Related Chronic Cough - GlobeNewswire
DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia - BioSpace
Drug film BXCL501 eases opioid withdrawal in Columbia University study - Stock Titan
AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV) - BioSpace
Rallybio Corporation and Candid Therapeutics Announce Merger Agreement - Business Wire
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM - Intellia Therapeutics
Intellia Therapeutics, Inc. (NTLA): A Bull Case Theory - Insider Monkey
Heron Therapeutics Inc expected to post a loss of 2 cents a shareEarnings Preview - TradingView
CAD-1005 Phase 2 data spur FDA EOP2 talks for Cadrenal (NASDAQ: CVKD) - Stock Titan
Cadrenal Therapeutics Announces Phase 2 Results with - GlobeNewswire
C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma - GlobeNewswire
VA-funded Phase 2 stenoparib trial begins for Allarity (NASDAQ: ALLR) - Stock Titan
Spotlight On Silence Therapeutics And 2 Other Promising Penny Stocks - Yahoo Finance
Allarity Therapeutics Doses First Patients in VA-Funded - GlobeNewswire
Perspective Therapeutics, Inc. (CATX) Builds Momentum With Funding and Trial Progress - Insider Monkey
0.14%
0.48%
자본화:
|
볼륨(24시간):